Pathstone Holdings
ABUS icon

Pathstone Holdings’s Arbutus Biopharma ABUS Stock Holding History

Pathstone Holdings’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$45K – 2338
2026
Q1 		$45K Hold
10,000
– – ﹤0.01% 2189
2025
Q4 		$48.1K Sell
10,000
-1,184
-11% -$5.32K ﹤0.01% 2190
2025
Q3 		$50.8K Buy
11,184
+1,184
+12% +$4.35K ﹤0.01% 2306
2025
Q2 		$30.9K Sell
10,000
-1,000
-9% -$3.32K ﹤0.01% 2158
2025
Q1 		$38.4K Sell
11,000
-88
-0.8% -$293 ﹤0.01% 2189
2024
Q4 		$36.3K Sell
11,088
-162
-1% -$596 ﹤0.01% 2276
2024
Q3 		$43.3K Buy
11,250
+593
+6% +$2.27K ﹤0.01% 2301
2024
Q2 		$32.9K Buy
10,657
+502
+5% +$1.51K ﹤0.01% 2282
2024
Q1 		$26.2K Hold
10,155
– – ﹤0.01% 2280
2023
Q4 		$25.4K Buy
+10,155
New +$19.9K ﹤0.01% 2185

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pathstone Holdings's ABUS Position: Q2 2026 in Review

Pathstone Holdings sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 10,000 shares — an estimated $45K sold.

Pathstone Holdings first reported a position in ABUS in Q4 2023 and held it in 10 quarters. The position peaked at $50.8K in Q3 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Pathstone Holdings reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • Pathstone Holdings sold 10,000 Arbutus Biopharma shares in Q2 2026, an estimated $45K.
  • Pathstone Holdings first reported a position in Arbutus Biopharma in Q4 2023 and held it in 10 quarters.
  • Pathstone Holdings's Arbutus Biopharma position peaked at $50.8K in Q3 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.